Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Ital J Gastroenterol Hepatol ; 31 Suppl 2: S190-4, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10604128

ABSTRACT

Neuroendocrine tumours of the gastro-entero-pancreatic tract are an uncommon clinical entity and are believed to arise from the endocrine cells of the gastrointestinal tract. Somatostatin receptor imaging is a diagnostic tool which allows visualization of somatostatin receptor bearing tumours. This scintigraphic procedure is performed with indium-111 labelled octreotide, a somatostatin analogue, chelated with diethylene triamine penta-acetic acid. Radionuclide imaging consists in detecting the biodistribution of somatostatin receptors, normally expressed on the cell surface of neuroendocrine gastro-entero-pancreatic tumours. To date, five types of this receptor have been cloned: indium-111-labelled-pentetreotide can visualize tumours expressing type 2 and 5 receptors. The results of our study, which involved 81 neuroendocrine gastro-entero-pancreatic tumour patients, confirm the superior sensitivity of somatostatin receptor imaging (61%) for primary tumour evaluation with respect to conventional imaging modalities such as computed tomography (40%) or ultrasound (28%). Scintigraphic findings in metastatic liver disease proved to have a sensitivity of 89% for somatostatin receptor imaging, versus 81% and 88% for computed tomography and ultrasound, respectively. In 23% of patients, lesions were found with somatostatin receptor imaging which had been missed using the other diagnostic modalities; in 26% of the patients the therapeutic approach was modified after somatostatin receptor imaging.


Subject(s)
Gastrointestinal Neoplasms/diagnostic imaging , Neuroendocrine Tumors/diagnostic imaging , Pancreatic Neoplasms/diagnostic imaging , Receptors, Somatostatin/analysis , Tomography, Emission-Computed, Single-Photon/methods , Adolescent , Adult , Aged , Aged, 80 and over , Female , Gastrointestinal Neoplasms/diagnosis , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuroendocrine Tumors/diagnosis , Octreotide , Pancreatic Neoplasms/diagnosis , Sensitivity and Specificity , Tomography, X-Ray Computed
2.
Eur J Nucl Med ; 25(10): 1396-403, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9818279

ABSTRACT

Neuroendocrine tumours displaying somatostatin receptors have been successfully visualised with somatostatin receptor imaging (SRI). However, there may be differences in sensitivity depending on the site of the primary tumour and/or its metastases. We studied 131 patients affected by neuroendocrine tumours of the gastro-entero-pancreatic (GEP) tract. A pathological diagnosis was obtained in 116 patients, while in 15 the diagnosis was based on instrumental results and follow-up. Fifty-one patients were examined for staging purposes, 80 were in follow-up. Images were acquired 24 and 48 h after the injection of 150-220 MBq of indium-111 pentetreotide. Whole-body and SPET images were obtained in all patients. Patients were also studied with computed tomography (CT), ultrasound (US), and other procedures. Tumours were classified according to their site of origin: pancreas n = 39, ileum n = 32, stomach n = 16, appendix n = 9, duodenum n = 5, jejunum n = 5, rectum n = 3, biliary tract n = 2, colon n = 2, caecum n = 1, liver metastases from unknown primary = 15, widespread metastases from unknown primary = 2. Sensitivity for primary tumour localisation was as follows: SRI = 62%; CT = 43%; US = 36%; other procedures = 45%. Sensitivity for liver metastases: SRI = 90%; CT = 78%; US = 88%; other procedures = 71%. Sensitivity for the detection of extrahepatic soft tissue lesions was: SRI = 90%; CT = 66%; US = 47%; other procedures = 61%. Sensitivity for the detection of the primary tumour in patients with metastases from unknown primary sites: SRI 4/17; CT 0/13; US 0/12; other procedures 1/10. In 28% of the patients SRI revealed previously unknown lesions, and in 21% it determined a modification of the scheduled therapy. Our study confirms the important role of SRI in the management of GEP tumours. However, we feel that a critical investigation should address its role in locating primary tumours, in particular in patients with metastases from unknown primary sites.


Subject(s)
Gastrointestinal Neoplasms/diagnostic imaging , Neuroendocrine Tumors/diagnostic imaging , Pancreatic Neoplasms/diagnostic imaging , Receptors, Somatostatin/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Female , Gastrointestinal Neoplasms/metabolism , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/secondary , Male , Middle Aged , Neuroendocrine Tumors/metabolism , Pancreatic Neoplasms/metabolism , Radiopharmaceuticals , Somatostatin/analogs & derivatives , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed , Ultrasonography , Whole-Body Counting
3.
Int J Biol Markers ; 13(1): 3-9, 1998.
Article in English | MEDLINE | ID: mdl-9681293

ABSTRACT

Neuroendocrine tumors (NETs) are rare neoplasms characterized by a low proliferative index and, in some cases, a favorable prognosis. These tumors often overproduce and release biologically active substances that are responsible for severe syndromes. Tumor marker measurement provides the clinician with useful information for the management of NET patients. The substances released by overproducing tumors are currently used as biomarkers, but there is a need for sensitive markers also for the "biochemically silent" NETs. The most effective and reliable blood marker available today is chromogranin A (CgA). Because of its high sensitivity and specificity, this glycoprotein can be used for the diagnosis, prognosis and followup of NETs. Furthermore, CgA measurement can be used for monitoring those tumors not over-producing or releasing any hormones or biological amines. This paper is a synthetic review on the value of CgA in NET management and reports our experiences with CgA measurement in NET patients.


Subject(s)
Biomarkers, Tumor/analysis , Chromogranins/analysis , Neuroendocrine Tumors/chemistry , Adenoma, Islet Cell/chemistry , Animals , Carcinoma, Medullary/chemistry , Carcinoma, Small Cell/chemistry , Chromogranin A , Humans , Neuroblastoma/chemistry , Pheochromocytoma/chemistry , Prognosis , Thyroid Neoplasms/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...